The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 135-141

  Polak, Paul E ^a   Lin, Shao Xia ^a   Pelligrino, Dale ^a   Feinstein, Douglas L ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Catecholamine; COMT; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Noradrenaline

Indexed keywords

3,5 DINITROCATECHOL; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; GAMMA INTERFERON; INTERLEUKIN 17; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NORADRENALIN; UNCLASSIFIED DRUG; CATECHOL DERIVATIVE; COMT PROTEIN, HUMAN; FREUND ADJUVANT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); NITRILE; OR486; PEPTIDE FRAGMENT;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME METABOLISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; SPINAL CORD; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; TIME; TOXICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; BLOOD-BRAIN BARRIER; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CATECHOLS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FREUND'S ADJUVANT; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NITRILES; PEPTIDE FRAGMENTS; SPINAL CORD; T-LYMPHOCYTES; TIME FACTORS;

EID: 84908539907     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.09.004     Document Type: Article

References (60)

1. Backstrom R., Honkanen E., Pippuri A., Kairisalo P., Pystynen J., Heinola K., Nissinen E., Linden I.B., Mannisto P.T., Kaakkola S. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem. 1989, 32:841-846.
2. Balkowiec-Iskra E., Kurkowska-Jastrzebska I., Joniec I., Ciesielska A., Czlonkowska A., Czlonkowski A. Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration. Acta Neurobiol. Exp. (Wars.) 2007, 67:379-388.
3. Barkhatova V.P., Zavalishin I.A., Askarova L.S., Shavratskii V.K., Demina E.G. Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav. Physiol. 1998, 28:341-344.
4. Benarroch E.E. The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009, 73:1699-1704.
5. Benson C.A., Wong G., Tenorio G., Baker G.B., Kerr B.J. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav. Brain Res. 2013, 252:302-311.
6. Bonifacio M.J., Palma P.N., Almeida L., Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev. 2007, 13:352-379.
7. Boullerne A.I., Polak P.E., Braun D., Sharp A., Pelligrino D., Feinstein D.L. Effects of peptide fraction and counter ion on the development of clinical signs in experimental autoimmune encephalomyelitis. J. Neurochem. 2014, 129:696-703.
8. Brannan T., Prikhojan A., Yahr M.D. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism. J. Neural Transm. 1997, 104:77-87.
9. Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog. Brain Res. 1991, 88:625-630.
10. De K.J., Zeinstra E., Wilczak N. Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol. Dis. 2004, 15:331-339.
11. Dubey R.K., Gillespie D.G., Zacharia L.C., Barchiesi F., Imthurn B., Jackson E.K. CY. Hypertension 2003, 41:807-813.
12. Eisenhofer G., Finberg J.P. Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J. Pharmacol. Exp. Ther. 1994, 268:1242-1251.
13. Fernandez-de-las-Penas C., mbite-Quesada S., Ortiz-Gutierrez R., Ortega-Santiago R., Gil-Crujera A., Caminero A.B. Catechol-O-methyltransferase Val158Met polymorphism (rs4680) is associated with pain in multiple sclerosis. J. Pain 2013, 14:1719-1723.
14. He Z., Sun X., Guo Z., Zhang J.H. Expression and role of COMT in a rat subarachnoid hemorrhage model. Acta Neurochir. Suppl. 2011, 110:181-187.
15. Helkamaa T., Finckenberg P., Louhelainen M., Merasto S., Rauhala P., Lapatto R., Cheng Z.J., Reenila I., Mannisto P., Muller D.N., Luft F.C., Mervaala E.M. Entacapone protects from angiotensin II-induced inflammation and renal injury. J. Hypertens. 2003, 21:2353-2363.
16. Helkamaa T., Reenila I., Tuominen R.K., Soinila S., Vaananen A., Tilgmann C., Rauhala P. Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem. Int. 2007, 51:412-423.
17. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 2002, 22:2434-2442.
18. Huang G., Dragan M., Freeman D., Wilson J.X. Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia 2005, 51:47-55.
19. Kambur O., Talka R., Ansah O.B., Kontinen V.K., Pertovaara A., Kalso E., Mannisto P.T. Inhibitors of catechol-O-methyltransferase sensitize mice to pain. Br. J. Pharmacol. 2010, 161:1553-1565.
20. Karaszewski J.W., Reder A.T., Anlar B., Arnason G.W. Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J. Neuroimmunol. 1993, 43:1-7.
21. Khoruzhaia T.A., Saakov B.A. Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis. Biull. Eksp. Biol. Med. 1975, 79:80-82.
22. Krenger W., Honegger C.G., Feurer C., Cammisuli S. Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J. Neurochem. 1986, 47:1247-1254.
23. Krenger W., Kabiersch A., Honegger C.G. Monoamines and related substances in brainstem and spinal cord of Lewis rats during the attack and recovery of experimental autoimmune encephalomyelitis. Brain Res. 1989, 491:374-378.
24. Learmonth D.A., Freitas A.P. Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug. Chem. 2002, 13:1112-1118.
25. Li L.S., Zheng L.F., Xu J.D., Ji T., Guo H., Li X.F., Li Y., Zhang Y., Zhu J.X. Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats. Neurogastroenterol. Motil. 2011, 23:657-e277.
26. MacKenzie F.J., Leonard J.P., Cuzner M.L. Changes in lymphocyte beta-adrenergic receptor density and noradrenaline content of the spleen are early indicators of immune reactivity in acute experimental allergic encephalomyelitis in the Lewis rat. J. Neuroimmunol. 1989, 23:93-100.
27. Mannisto P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
28. Marcocci L., Maguire J.J., Packer L. Nitecapone: a nitric oxide radical scavenger. Biochem. Mol. Biol. Int. 1994, 34:531-541.
29. Marien M.R., Colpaert F.C., Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 2004, 45:38-78.
30. Markianos M., Koutsis G., Evangelopoulos M.E., Mandellos D., Karahalios G., Sfagos C. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J. Neurochem. 2009, 108:158-164.
31. Markianos M., Sfagos C., Bistolaki E. Platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in patients with multiple sclerosis. Acta Neurol. Scand. 1991, 84:531-533.
32. Muller T. Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer. Adherence 2009, 3:51-59.
33. Muller T., Kuhn W., Przuntek H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?. J. Neural Transm. Gen. Sect. 1993, 92:187-195.
34. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., Baker G.B., Kerr B.J. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav. Immun. 2011, 25:1677-1688.
35. Myohanen T.T., Schendzielorz N., Mannisto P.T. Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J. Neurochem. 2010, 113:1632-1643.
36. Nissinen E., Linden I.B., Schultz E., Kaakkola S., Mannisto P.T., Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 1988, 153:263-269.
37. Nord M., Zsigmond P., Kullman A., Arstrand K., Dizdar N. The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF. Mov. Disord. 2010, 25:363-367.
38. Ogburn K.D., Bottiglieri T., Wang Z., Figueiredo-Pereira M.E. Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol. Dis. 2006, 22:294-301.
39. Picazo O., Azcoitia I., Garcia-Segura L.M. Neuroprotective and neurotoxic effects of estrogens. Brain Res. 2003, 990:20-27.
40. Polak P.E., Kalinin S., Braun D., Sharp A., Lin S.X., Feinstein D.L. The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the locus coeruleus. J. Neurochem. 2012, 121:206-216.
41. Polak P.E., Kalinin S., Feinstein D.L. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2011, 134:665-677.
42. Rajda C., Bencsik K., Fuvesi J., Seres E., Vecsei L., Bergquist J. The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult. Scler. 2006, 12:265-270.
43. Rajda C., Bencsik K., Vecsei L.L., Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J. Neuroimmunol. 2002, 124:93-100.
44. Redell J.B., Dash P.K. Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia. Neurosci. Lett. 2007, 413:36-41.
45. Saragea M., Rotaru N., Negru T., Vladutiu A. Monoamine oxidase and acetylcholinesterase activity in animals with experimental allergic encephalomyelitis. Nature 1965, 206:306-307.
46. Schaible E.V., Windschugl J., Bobkiewicz W., Kaburov Y., Dangel L., Kramer T., Huang C., Sebastiani A., Luh C., Werner C., Engelhard K., Thal S.C., Schafer M.K. 2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1alpha response after traumatic brain injury in mice. J. Neurochem. 2014, 129:940-954.
47. Schendzielorz N., Rysa A., Reenila I., Raasmaja A., Mannisto P.T. Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats. J. Physiol. Pharmacol. 2011, 62:483-490.
48. Segall S.K., Nackley A.G., Diatchenko L., Lariviere W.R., Lu X., Marron J.S., Grabowski-Boase L., Walker J.R., Slade G., Gauthier J., Bailey J.S., Steffy B.M., Maynard T.M., Tarantino L.M., Wiltshire T. Comt1 genotype and expression predicts anxiety and nociceptive sensitivity in inbred strains of mice. Genes Brain Behav. 2010, 9:933-946.
49. Singh A., Kulkarni S.K. Role of adenosine in drug-induced catatonia in mice. Indian J. Exp. Biol. 2002, 40:882-888.
50. Tajouri L., Martin V., Gasparini C., Ovcaric M., Curtain R., Lea R.A., Haupt L.M., Csurhes P., Pender M.P., Griffiths L.R. Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Res. Bull. 2006, 69:327-331.
51. Venugopala K.N., Rashmi V., Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed. Res. Int. 2013, 2013:963248.
52. Verhagen-Kamerbeek W.D., Hazemeijer I., Korf J., Lakke J.P. Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. J. Neural. Transm. Park. Dis. Dement. Sect. 1993, 6:17-26.
53. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr. Alzheimer Res. 2008, 5:342-345.
54. White S.R., Bhatnagar R.K., Bardo M.T. Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J. Neurochem. 1983, 40:1771-1773.
55. Wiegmann K., Muthyala S., Kim D.H., Arnason B.G., Chelmicka-Schorr E. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J. Neuroimmunol. 1995, 56:201-206.
56. Xie T., Ho S.L., Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 1999, 56:31-38.
57. Zeng B.Y., Balfour R.H., Jackson M.J., Rose S., Jenner P. Expression of catechol-O-methyltransferase in the brain and periphery of normal and MPTP-treated common marmosets. J. Neural Transm. 2010, 117:45-51.
58. Zhao W.Q., Latinwo L., Liu X.X., Lee E.S., Lamango N., Charlton C.G. l-DOPA upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase. Exp. Neurol. 2001, 171:127-138.
59. Zoukos Y., Leonard J.P., Thomaides T., Thompson A.J., Cuzner M.L. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann. Neurol. 1992, 31:657-662.
60. Zoukos Y., Thomaides T., Mathias C.J., Cuzner M.L. High beta-adrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction?. Acta Neurol. Scand. 1994, 90:382-387.